Bombay HC slams FDA; Cipla licence cancellation order revoked
The Maharashtra FDA has revoked its decision to cancel the drug sale licence for Cipla Pharma & Life Sciences’ Pune unit. This move follows sharp criticism from the Bombay High Court, which described the regulator's previous action as 'overboard.' The FDA stated it plans to issue a new show-cause notice and will provide a formal, reasoned order moving forward. The initial cancellation was linked to claims of irregularities regarding the packaging, storage, and recall of Reactin Plus tablets.